Table 3.

Secondary outcomes in this study.

(a) Incidence and Severity of Respiratory Tract Infections in Each Group
					K15 (n = 20)		Placebo (n = 18)		p
Incidence of respiratory tract infections, n (%)					20 (100)		16 (88.9)		0.2176
Total days of respiratory tract infections, median [range]					41.5 [2–129]		35.5 [0–334]		0.8378
Respiratory syncytial virus infection, n (%)					1 (5.0)		1 (5.6)		>0.9999
Hospital visit, n (%)					19 (95.0)		16 (88.9)		0.5946
Total days of hospital visits, median [range]					4.5 [0–17]		4.5 [0–29]		0.9066
Hospital admission with respiratory tract infection, n (%)					0 (0.0)		2 (11.1)		0.2065
Oxygen use, n (%)					0 (0.0)		2 (11.1)		0.2065
Mechanical ventilation, n (%)					0 (0.0)		2 (11.1)		0.2065
(b) The changes in serum IgG, IgA, and IgM levels between, before and after the study period in each group
	IgG, mg/dL (mean ± SD)			IgA, mg/dL (mean ± SD)			IgM, mg/dL (mean ± SD)
	Before	After	p	Before	After	p	Before	After	p
K15 (n = 20)	383 ± 189	566 ± 129	0.4882	<10.0 ± 0.0	27.6 ± 13.4	0.2509	23.7 ± 12.4	81.5 ± 29.3	0.5094
Placebo (n = 18)	371 ± 209	602 ± 184		<10.0 ± 0.0	35.0 ± 24.6		21.4 ± 5.9	67.7 ± 26.7
(c) Adverse effects in each group during the study period
					K15 (n = 20)		Placebo (n = 18)		p
Gastrointestinal tract symptoms, n (%)					13 (65.0)		12 (66.7)		>0.9999
Total days with gastrointestinal tract symptoms, mean ± SD					12.4 ± 25.5		7.8 ± 17.9		0.8474
Skin symptoms, n (%)					11 (55.0)		6 (33.3)		0.2097
Total days with skin symptoms, mean ± SD					4.2 ± 7.8		3.1 ± 6.3		0.6000

IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M. SD: standard deviation.